BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1944 related articles for article (PubMed ID: 8516616)

  • 21. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J; Chen Y; Moyana T
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
    Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
    Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor immunotherapy in melanoma: on the dawn of a new era?
    Wilcox R; Markovic SN
    Curr Opin Mol Ther; 2007 Feb; 9(1):70-8. PubMed ID: 17330404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of T cell receptor alpha beta variability in tumor-infiltrating lymphocytes in primary and metastatic melanoma.
    Zeuthen J; Birck A; Straten PT
    Arch Immunol Ther Exp (Warsz); 1995; 43(2):123-33. PubMed ID: 8744727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor tissue recycling--a new combination treatment for solid tumors: experimental and preliminary clinical research.
    Li B; Ding J; Larson A; Song S
    In Vivo; 1999; 13(5):433-8. PubMed ID: 10654199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
    Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
    Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ; Parkinson DR; Marincola F
    J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid expansion of tumor-reactive cells from HLA-matched siblings for adoptive immunotherapy of melanoma.
    Gottlieb DJ; Micklethwaite K; Bradstock KF; Li YC
    Cytotherapy; 2007; 9(2):133-43. PubMed ID: 17453965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the biological therapy and gene therapy of malignant disease.
    Hersh EM; Stopeck AT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2623-9. PubMed ID: 10068264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy dispenses with tumor antigens.
    Ferrone S
    Nat Biotechnol; 2004 Sep; 22(9):1096-8. PubMed ID: 15340476
    [No Abstract]   [Full Text] [Related]  

  • 34. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Application of gene therapy in tumor adoptive immunotherapy].
    Wang C; Zhao Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy.
    Bodey B; Kaiser HE; Goldfarb RH
    Anticancer Res; 1996; 16(1):517-31. PubMed ID: 8615665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
    Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
    Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches].
    Enk AH; Becker JC; Schuler G
    J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Rational bases for new approaches to the therapy of pediatric solid tumors: immunotherapy and gene therapy].
    Pistoia V; Prigione I; Facchetti P; Corrias MV
    Pediatr Med Chir; 1994; 16(3):219-25. PubMed ID: 7971443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Future aspects of immunotherapy and gene therapy in neuroblastoma.
    Aktas S
    J BUON; 2009 Sep; 14 Suppl 1():S175-9. PubMed ID: 19785063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 98.